Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:02:02.653Z.
Calculation as of: 2026-10-06T18:02:02.653Z.
Quote observation: 2026-10-06T17:57:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$34.21M
EV/FCF Ratio
N/A
TTM Avg
17.34x
3Y Avg
44.12x
5Y Avg
46.63x
Market Cap
$35.69M
EV/FCF Ratio
N/A
TTM Avg
509.31x
3Y Avg
509.31x
5Y Avg
509.31x
Market Cap
$32.82M
EV/FCF Ratio
N/A
TTM Avg
13.12x
3Y Avg
13.45x
5Y Avg
13.45x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.48M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.42M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.21M | N/A | 17.34x | 44.12x | 46.63x |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.59M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | N/A | 509.31x | 509.31x | 509.31x |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.26M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.81M | N/A | 1.82x | 3.39x | 16.62x |
| Scilex Holding Company (SCLX)vs › | $32.82M | N/A | 13.12x | 13.45x | 13.45x |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute